Bizarre Patents
A Receptacle for supporting, rotating and sculpting a portion of ice cream or similarly malleable food while it is being consumed.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128713 | Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus Replication-defective vaccine vectors against respiratory syncytial virus (RSV) are disclosed. Corresponding compositions and methods employing the vaccine vectors are also disclosed.... | 05/24/2012 |
| 20120128714 | Alphavirus Replicon Particles Expressing TRP2 The immune response to melanoma cells and tumors can be induced or significantly increased by administering to a subject a pharmaceutical composition comprising alphavirus particles, especially Venezuelan equine encephalitis virus replicon particles, which express the m... | 05/24/2012 |
| 20120107347 | COMBINATION IMMUNOTHERAPY COMPOSITIONS AGAINST CANCER AND METHODS Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer... | 05/03/2012 |
| 20120082696 | INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA) The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furtherm... | 04/05/2012 |
| 20120052089 | NEWCASTLE DISEASE VIRUS VECTORED HERPESVIRUS VACCINES The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compo... | 03/01/2012 |
| 20120045471 | RECOMBINANT PARAINFLUENZA VIRUS VACCINE COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM RESPIRATORY SYNCYTIAL VIRUS The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or pre... | 02/23/2012 |
| 20120034256 | HCV VACCINES AND METHODS FOR USING THE SAME Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are di... | 02/09/2012 |
| 20120035529 | TUMOR VASCULAR MARKER-TARGETED VACCINES The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in... | 02/09/2012 |
| 20120020995 | PARAPOXVIRUS VECTORS The present invention relates to recombinant parapoxviruses comprising heterologous DNA derived from a canine distemper virus, to the preparation of such constructs, and to their use in immunogenic compositions and vaccines. It further relates to the use of recombinant ... | 01/26/2012 |
| 20120020994 | MULTIVALENT, DRYING RESISTANT, EVOLUTION-BASED VACCINES Disclosed is a recombinant nonpermutated bacteriophage that includes a nucleic acid sequence that is at least 150 kb in length wherein the bacteriophage is made to display one or more surface antigens such as heterologous polypeptides, and compositions and kits that inc... | 01/26/2012 |
| 20120014988 | REPLICATION DEFICIENT RECOMBINANT VIRUSES EXPRESSING ANTIGENS REGULATED BY TRANSCRIPTIONAL CONTROL ELEMENTS COMPRISING MULTIPLE ELEMENTS The present invention relates to a replication deficient recombinant virus encoding at least one antigen and/or antigenic epitope, wherein expression of said antigen and/or antigenic epitope is regulated by a transcriptional control element comprising at least two eleme... | 01/19/2012 |
| 20120009214 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.... | 01/12/2012 |
| 20120003264 | CDNA Corresponding to the Antigenome of Nonsegmented Negative Stranded RNA Viruses and Process for the Production of Such Viruses The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in s... | 01/05/2012 |
| 20120003263 | RECOMBINANT RACCOON POX VIRUS VACCINE AGAINST HIGHLY PATHOGENIC AVIAN INFLUENZA Vaccines comprising one or more recombinant raccoon pox viruses and methods of using those vaccines to immunize avians.... | 01/05/2012 |
| 20110311579 | Flaviviruses expressing the prM, E, and NS1 proteins of other flaviviruses and uses thereof This invention provides flavivirus vaccines that comprise live-attenuated flaviviruses and methods of making and using these vaccines. The flavivirus vaccines described herein possess higher potency due to in situ production of additional immunogens in a way that mimics... | 12/22/2011 |
| 20110311578 | RECOMBINANT INACTIVATED VIRAL VECTOR VACCINE A vaccine is described, comprising an inactivated viral vector having inserted an exogenous nucleotide sequence coding for a disease of concern; and, a pharmaceutically acceptable vehicle, adjuvant or excipient, which provides due protection against the disease of conce... | 12/22/2011 |
| 20110311580 | Settings for recombinant adenoviral-based vaccines Described are new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, also described are new assays to determine the best regimen for applying the most suita... | 12/22/2011 |
| 20110305713 | METHODS AND COMPOSITIONS TO ENHANCE VACCINE EFFICACY BY REPROGRAMMING REGULATORY T CELLS The immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by a subset of murine plasmacytoid DCs (pDCs) in tumor-draining LNs, where it can potently activate Foxp3 regulatory T cells (Tregs). We now show that IDO functions as a molecular switch in tumor... | 12/15/2011 |
| 20110305664 | NOVEL VACCINES AGAINST MULTIPLE SUBTYPES OF INFLUENZA VIRUS An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is cap... | 12/15/2011 |
| 20110300176 | Microorganisms for therapy Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so t... | 12/08/2011 |
| 20110293655 | Porcine Adenovirus 3-Based PRRSV Vaccines The invention relates to a porcine adenovirus 3 based vaccine for the treatment of PRRS virus infection where the PADV3 is a recombinant replication competent PADV3 that comprises a nucleic acid that encodes a novel fusion protein of PRRSV ORF6 and a modified PRRSV ORF5... | 12/01/2011 |
| 20110293656 | RECOMBINANT MVA CAPABLE OF EXPRESSING STRUCTURAL HCV ANTIGENS The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form o... | 12/01/2011 |
| 20110287050 | RECOMBINANT KOI HERPESVIRUS (KHV) OR CYPRINID HERPESVIRUS 3 (CYHV-3) AND A VACCINE FOR THE PREVENTION OF A DISEASE CAUSED BY KHV/CYHV-3 IN CYPRINUS CARPIO CARPIO OR CYPRINUS CARPIO KOI The present invention refers to a recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3), which is immunogenic in fish, preferably in carps, more preferably in Cyprinus carpio, and to a vaccine for preventive and/or therapeutic treatment of a diseas... | 11/24/2011 |
| 20110287051 | PARAPOXVIRUS VECTORS The present invention relates to recombinant parapoxviruses which carry in their genomes comprising heterologous DNA derived from a rabies virus, to the preparation of such constructs, and to their use in immunogenic compositions and vaccines. It further relates ... | 11/24/2011 |
| 20110274649 | T-CELL VACCINATION WITH VIRAL VECTORS VIA MECHANICAL EPIDERMAL DISRUPTION Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parasitic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount... | 11/10/2011 |
| 20110262474 | Chimeric HIV Antigens The invention provides polynucleotides and polypeptides encoded therefrom that are capable of inducing immune responses to a human immunodeficiency virus. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.... | 10/27/2011 |
| 20110256174 | RABIES VACCINE An attenuated rabies virus for use as a vaccine. The attenuated rabies virus expresses an immune factor that enhances immune response upon administration of the vaccine.... | 10/20/2011 |
| 20110250228 | Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or ... | 10/13/2011 |
| 20110243972 | PROSTATE STEM CELL ANTIGEN VACCINES AND USES THEREOF This invention relates to the identification of prostate stem cell antigen (PSCA) as a target of clinically relevant antitumor immune responses. The invention provides vaccines comprising PSCA, or fragments thereof, which are useful in inducing antitumor immune response... | 10/06/2011 |
| 20110243986 | POLYNUCLEOTIDES ALLOWING THE EXPRESSION AND SECRETION OF RECOMBINANT PSEUDO-VIRUS CONTAINING FOREIGN EPITOPES, THEIR PRODUCTION, AND USE This invention provides a new approach to the design of a virus with a defective replication cycle, which can be rescued by wild type virus co-infection, and which expresses foreign antigenic epitopes that contribute to the elimination of virus infected cells and then t... | 10/06/2011 |
| 20110236417 | VACCINES COMPRISING MUTANT ATTENUATED INFLUENZA VIRUSES The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein with ... | 09/29/2011 |
| 20110236415 | VIRULENT ONCOLYTIC HERPES SIMPLEX VIRUS STRAINS ENGINEERED TO COUNTER THE INNATE HOST RESPONSE The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ134.5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an... | 09/29/2011 |
| 20110236416 | FOOT AND MOUTH DISEASE VIRUS RECOMBINANT VACCINES AND USES THEREOF The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which c... | 09/29/2011 |
| 20110236468 | VACCINE COMPOSITIONS The present invention relates, inter alia, to a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more viral vectors comprising one or more heterol... | 09/29/2011 |
| 20110229514 | VACCINE AND IMMUNIZATION METHOD USING PLASMODIUM ANTIGEN 2 A vaccine comprising an immunogenic preparation containing a plasmodium antigen or a fragment thereof, wherein said antigen is selected from a group consisting of PyAg2, PfAg2, PvAg2, PkAg2, PoAg2, PmAg2, PbAg2, PcAg2 and a combination thereof. A vaccination meth... | 09/22/2011 |
| 20110217328 | COMPOSITIONS AND METHODS FOR TREATING EBOLA VIRUS INFECTION The compositions and methods of the invention described herein provide treatments against Ebola virus infection by expressing gene(s) from the Ivory Coast ebolavirus (ICEBOV) species in a recombinant viral vector.... | 09/08/2011 |
| 20110212126 | INACTIVATED CHIMERIC VACCINES AND RELATED METHODS OF USE Embodiments of the present invention provide an inactivated chimeric virus and immunogenic compositions for the treatment or prevention of infection with West Nile virus. Further, other embodiments of the present invention relate to methods of preventing and treating We... | 09/01/2011 |
| 20110206710 | Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine Use of a recombinant lentiviral vector comprising a polynucleotide fragment encoding at least one protein of a virus of the family Flaviviridae or an immunogenic peptide of at least 8 amino acids of said protein, for preparing a pharmaceutical composition intended for t... | 08/25/2011 |
| 20110189224 | PESTIVIRUS REPLICONS PROVIDING AN RNA-BASED VIRAL VECTOR SYSTEM The present invention concerns replicons of pestiviruses, in particular replicons of swine fever virus, engineered to have a defective replication thereby having lost infectivity, and further containing a foreign gene. A replicon of the invention contains all the geneti... | 08/04/2011 |
| 20110182933 | MODIFIED VACCINIA ANKARA VIRUS VARIANT The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes whe... | 07/28/2011 |
